IDiyas

For the Inventor, By the Inventor

Santa Barbara, CA, United States of America

Matthew Bio

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Santa Barbara, CA (US) (2016 - 2018)
  • Belmont, MA (US) (2017 - 2019)

Company Filing History:

goldMedal9 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2016-2019

where 'Filed Patents' based on already Granted Patents

9 patents (USPTO):
1. 10344041 - Polymorphic forms and co-crystals of a c-Met inhibitor (2019-07-09),
2. 10053452 - Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof (2018-08-21),
3. 9981988 - Polymorphic forms and co-crystals of a c-Met inhibitor (2018-05-29),
4. 9855259 - Processes of making and crystalline forms of a MDM2 inhibitor (2018-01-02),
5. 9801867 - Processes of making and crystalline forms of a MDM2 inhibitor (2017-10-31),
6. 9643984 - Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines (2017-05-09),
7. 9623018 - Processes of making and crystalline forms of a MDM2 inhibitor (2017-04-18),
8. 9376386 - Processes of making and crystalline forms of a MDM2 inhibitor (2016-06-28),
9. 9296735 - Method for the preparation of thiadiazoles (2016-03-29),

Title: The Innovative Contributions of Matthew Bio

Introduction

Matthew Bio is a prominent inventor based in Santa Barbara, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of nine patents to his name, Bio's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents is a groundbreaking invention related to polymorphic forms and co-crystals of a c-Met inhibitor. This invention provides novel polymorphic forms and co-crystals of a compound that is useful in the treatment, prevention, or amelioration of cancer. Specifically, it includes polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which acts as an inhibitor of c-Met. Another notable patent involves crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts. This invention relates to the crystalline and co-crystal forms of pharmaceutically acceptable salts of the compound, which is aimed at treating various types of cancer, including solid tumors and hematologic cancers such as myeloma and leukemia.

Career Highlights

Matthew Bio is currently employed at Amgen Inc., a leading biotechnology company known for its innovative approaches to medicine. His work at Amgen has allowed him to focus on developing new therapeutic options for cancer patients, showcasing his commitment to advancing medical science.

Collaborations

Throughout his career, Bio has collaborated with notable colleagues, including Yuanqing Fang and Sebastien Caille. These collaborations have further enriched his research and contributed to the success of his inventions.

Conclusion

Matthew Bio's contributions to the field of pharmaceuticals, particularly in cancer treatment, highlight his innovative spirit and dedication to improving patient outcomes. His patents reflect a commitment to advancing medical science and offer hope for new therapeutic options in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…